-
€249.99 Incl. VAT
Our list of the largest pharmaceutical companies in Germany provides you with comprehensive insights into the most important players in the German pharmaceutical industry. In addition to current revenue and employee figures, you will also find valuable information on industry focus, executives, and contact details. The data is conveniently available as an Excel file for direct download.
What is the Highest-Revenue German Pharmaceutical Company in 2025?
Boehringer Ingelheim is, according to intensive research by ResearchGermany – and the latest financial statements available in the German Federal Gazette (as of 2.9.2025) – the highest-revenue German pharmaceutical company in 2025. The family-owned company reported consolidated revenue of €25.6 billion for 2023 (currency-adjusted +9.7%). For 2024, €26.8 billion is reported. Based on pharmaceutical revenue, Boehringer is ranked as the largest German pharmaceutical group. Particularly strong: Human Pharma with €20.8 billion (+10.3%) driven by JARDIANCE® and OFEV®, as well as Animal Health with €4.7 billion (+6.9%).
Why Boehringer Leads (Key Facts 2023/2024)
- Revenue 2023: €25.6 billion (group-wide; +9.7% currency-adjusted)
- Human Pharma 2023: €20.8 billion (+10.3%)
- Animal Health 2023: €4.7 billion (+6.9%)
- R&D 2023: €5.8 billion (22.5% of revenues)
- Revenue 2024: €26.8 billion; R&D 2024: €6.2 billion; Employees 2024: approx. 54,500
Note for context: Groups like Bayer achieve higher total revenues, but only part comes from the pharma business (around €18 billion at Bayer) – thus below Boehringer.
Alternative Candidates Compared
| Company | Legal Form | Industry/Segment | Group Revenue 2023 | Pharma-Relevant Assessment | Employees 2023 | Headquarters |
|---|---|---|---|---|---|---|
| Boehringer Ingelheim International GmbH | GmbH & Co. KG | Pharma (Human & Animal Health) | €25.611 billion | #1 Pharma in DE (2025) | 53,565 | Ingelheim am Rhein |
| Bayer AG | AG | Chemicals (Pharma, Agrochemicals) | €47.637 billion | Only ~€18 billion in Pharma segment ⇒ below Boehringer | 99,723 | Leverkusen |
| Merck KGaA | KGaA | Healthcare, Life Science, Performance Materials | €20.993 billion | Only part is Healthcare/Pharma ⇒ below Boehringer | 62,908 | Darmstadt |
| BioNTech SE | SE | Biotech (mRNA Drugs/Vaccines) | €3.819 billion | Clearly below Boehringer | 5,640 | Mainz |
| Abbott GmbH (DE) | GmbH | Pharma/Medical Devices/Nutrition | €5.997 billion | German subsidiary; below Boehringer | – | Wiesbaden |
Data basis: All figures, segments, and classifications are based on the provided information (incl. Boehringer annual data 2023/2024 as well as 2023 comparison data of the listed companies from the Federal Gazette, compiled in the exclusive ResearchGermany list of the largest pharmaceutical companies). The decisive criterion for the ranking is pharma revenue – not total group revenue from non-pharma segments.
Conclusion
Based on the 2023/2024 figures, Boehringer Ingelheim remains Germany’s highest-revenue pharmaceutical company in 2025. Competitors such as Bayer and Merck KGaA rank lower in pure pharma comparison, as significant parts of their revenues come from non-pharma segments.
Image source: A.C., 02.09.2025
Also relevant here: the article on the 2025 update of the leading ResearchGermany database of the largest German pharmaceutical companies.
Last Updated on 4 months ago
